Navigation Links
Discovery could increase efficacy of promising cystic fibrosis drug
Date:3/21/2013

A little more than a year after the FDA approved Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, University of Missouri researchers believe they have found exactly how this drug works and how to improve its effectiveness in the future. Described in the current issue of the Proceedings of the National Academy of Sciences, MU researchers have redefined a key regulatory process in the defective protein responsible for cystic fibrosis that could change the way scientists approach the lethal genetic disease.

"They know the drug works, but they don't know how it works or where it works," said Tzyh-Chang Hwang, PhD, PNAS corresponding author and professor of medical pharmacology and physiology at the MU School of Medicine. "Our paper provides a theory for how Vx-770 works, and based on our understanding of how the CFTR channel works, we have identified a novel strategy for future explorations to complement and enhance the performance of the existing drug."

Cystic fibrosis is the second most common life-shortening inherited disorder occurring in childhood in the United States, after sickle cell anemia. Approximately 30,000 Americans have cystic fibrosis, and there are an estimated 1,000 new cases diagnosed each year. Cystic fibrosis patients are born with a genetic defect that causes a malfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel in the cell membrane that plays a critical role in maintaining water and salt balance across many body tissues, such as sweat glands, tissues that line the lungs, liver, pancreas and reproductive organs.

"The chloride channel is like a pipe that allows ions to travel through at a very fast pace," Hwang said. "In cystic fibrosis patients the channel is dysfunctional and activity is diminished. So what is the mechanism that controls the opening and closing of the channel? That is the fundamental disco
'/>"/>

Contact: Michael Muin
muinm@health.missouri.edu
573-884-7541
University of Missouri School of Medicine
Source:Eurekalert  

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
2. Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012
3. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
4. Unexpected discovery reveals a new mechanism for how the cerebellum extracts signal from noise
5. Discovery offers insight into treating viral stomach flu
6. Breast cancer risk gene discovery fast tracked by new technology
7. Tales from the crypt lead researchers to cancer discovery
8. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
9. Stomata development in plants unraveled -- a valuable discovery for environmental research
10. Discovery reveals chromosomes organize into yarns
11. Bacteria discovery could lead to antibiotics alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Discovery could increase efficacy of promising cystic fibrosis drug
(Date:5/24/2013)... Frontiers, one of the world,s largest and fastest growing ... journal, Frontiers in Physics . , A broad ... will provide an open-science and interactive web platform ... rigorously peer-reviewed articles. , Frontiers, real-time and interactive ... range of article types. With an average of three ...
(Date:5/24/2013)... scientists have focused among other factors on drugs ... is the accumulation of A-beta that causes the known plaques ... formation of A-beta is APP. Alessia Soldano and Bassem Hassan ... APPL the fruit-fly version of APP in the ... Leuven): "We have discovered that APPL ensures that brain cells ...
(Date:5/23/2013)... year, carrying more than 284 million tons of cargo, transit ... in toll fees for the Panama Canal Authority. Each time ... water are used from Gatun Lake, which is also a ... the isthmus. , However, the advent of very large ... ships at sea, has demanded change. The Panama Canal is ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... Mutations that are found in stem cells could be ... reason the disease recurs. These abnormal cells are likely controlling ... targeted by chemotherapy and radiation, they enable the disease to ... by scientists and physicians at the Oregon Health & Science ...
... Maurice Godfrey, PhD, Associate Professor of Pediatrics in ... Center, was recently awarded a $10,000 grant from the ... titled, "Luck of the Draw An Ethics Values ... Genetics Education Research Program. The primary goal of ASHG,s ...
... -- Today, oxygen takes up a hefty portion of Earth,s ... air we breathe. However, very early in Earth,s history, O2 ... in the turbulent mix of primordial gases. It wasn,t until ... when oxygen made any measurable dent in the atmosphere, stimulating ...
Cached Biology News:Malignant stem cells may explain why some breast cancers develop and recur 2MIT: Oxygen's watery past 2MIT: Oxygen's watery past 3
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
Breaking Biology Technology:DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... SHANGHAI, Feb. 28, 2011 /PRNewswire-Asia-FirstCall/ -- ShengdaTech, Inc. ("ShengdaTech" ... leading manufacturer of nano-precipitated calcium carbonate ("NPCC") in China, ... and CEO, Ms. Anhui Guo, COO and acting CFO ... attend the Rodman & Renshaw Annual China Investment Conference ...
... announces a special edition of its Key ... Disease Day 2011 , an international event to raise awareness ... Dialogue spanned two continents and provided a platform ... caregivers and healthcare providers. (Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO) ...
... VILLAGE, Nev., Feb. 28, 2011 PDL BioPharma, Inc. ... it has entered into a definitive settlement agreement with ... settlement agreement, PDL agreed to dismiss its claims against ... includes Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd ...
Cached Biology Technology:ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 3Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 4Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 5PDL Settles Litigation and Resolves Other Disputes 2
... Rabbit Tissue Arrays contain 60 rabbit tissue samples ... contains 4 unstained slides and 1 hematoxylin and ... slide contains 15 different tissues from 4 rabbit ... per slide. Each tissue sample (or core) is ...
A univariate (peak height or area) quantitative multi-component analysis package....
... represents a major advance in liquid dispensing ... of large robotic liquid handlers into the ... accurate volumes ranging from 10mL to 2mL ... advantages not yet found in other benchtop ...
... pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L ... and magnesium chloride. The use of a ... is generally attributed to early workers in ... a solution of inorganic salts designed to ...
Biology Products: